search

Active clinical trials for "Macular Degeneration"

Results 311-320 of 1337

HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular...

Wet Macular DegenerationMacular Degeneration1 more

In this fifth year of anti-VEGF therapy for neovascular AMD, retinal physicians are collecting groups of patients who either do not or only partially respond to anti-VEGF therapy. This study will evaluate the efficacy and safety of 2mg ranibizumab specifically for patients with fibrovascular PEDs that have not resolved following at least 6 consecutive injections of ranibizumab or bevacizumab over the previous 12 months. The investigators hypothesize that the 2mg dose will be able to completely eliminate the persistent PEDS in these patients.

Terminated22 enrollment criteria

Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment...

Age-Related Macular Degeneration

To determine if patients treated early after diagnosis of wet age-related macular degeneration can return/maintain to their baseline pre-disease BCVA.

Terminated10 enrollment criteria

Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal...

Subfoveal Choroidal NeovascularizationAge-Related Maculopathy

This study will evaluate the safety and efficacy of dexamethasone (OZURDEX®) as adjunctive therapy to ranibizumab (LUCENTIS®) compared with ranibizumab alone in the treatment of patients with choroidal neovascularization secondary to age-related macular degeneration

Terminated6 enrollment criteria

Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular...

Age-related Macular DegenerationChoroidal Neovascularization

The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation via different injection routes in patients with treatment-naive sub-foveal choroidal neovascularization secondary to age-related macular degeneration.

Terminated5 enrollment criteria

The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration

Choroidal Neo-Vascular Age-onset Macular DegenerationAge-related Macular Degeneration

The study will assess the safety and efficacy of Everolimus (RAD001) alone or in combination with Lucentis in patients with neo-vascular age related macular degeneration (AMD)

Terminated8 enrollment criteria

TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration...

Age-Related Macular Degeneration

VERTACL will investigate whether a triple therapy, Avastin®, half fluence verteporfin photodynamic therapy (PDT), and triamcinolone acetonide-preservative free (TAC- PF), results in improved 12-month vision outcome compared to Avastin® alone in participants with neovascular AMD.

Terminated18 enrollment criteria

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination...

Age-Related Macular Degeneration

The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).

Terminated8 enrollment criteria

Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination...

Age-related Macular Degeneration

The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy.

Terminated6 enrollment criteria

A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants...

Geographic Atrophy

This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Terminated7 enrollment criteria

A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants...

Geographic Atrophy

This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Terminated9 enrollment criteria
1...313233...134

Need Help? Contact our team!


We'll reach out to this number within 24 hrs